Page last updated: 2024-11-09

4-(1,3-benzodioxol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylic acid ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID660084
CHEMBL ID1351275
CHEBI ID108037
SCHEMBL ID14413641

Synonyms (33)

Synonym
OPREA1_213195
STK103210
ethyl 4-(1,3-benzodioxol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
MLS000027390
smr000059266
OPREA1_145250
CHEBI:108037
AKOS000291381
ethyl 4-(1,3-benzodioxol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate
AKOS002275640
ethyl 6-(1,3-benzodioxol-5-yl)-2-hydroxy-4-methyl-1,6-dihydropyrimidine-5-carboxylate
STK961722
CCG-15408
HMS2320N22
CHEMBL1351275
AKOS016312269
AB00074682-01
AKOS016037949
161374-09-0
JS-1555
ethyl 4-(2h-1,3-benzodioxol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
SCHEMBL14413641
Q27186499
4-(1,3-benzodioxol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylic acid ethyl ester
sr-01000456139
SR-01000456139-1
sr-01000000929
SR-01000000929-2
Z47751403
ethyl4-(2h-1,3-benzodioxol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
CS-0320861
ethyl 4-(benzo[d][1,3]dioxol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
cl-435229
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency199.52605.623417.292931.6228AID485281
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency3.54810.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.63100.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID654127Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654130Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654128Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654126Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654125Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654124Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654115Antioxidant activity assessed as scavenging of DPPH at 160 uM after 30 mins by spectrophotometry2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID654129Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Free radical scavenging and antiproliferative properties of Biginelli adducts.
AID1153368Inhibition pig alpha-amylase at 50 to 300 ug/ml pretreated for 30 mins followed by addition of 1% starch for 10 mins by spectrometer2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Graphite catalyzed solvent free synthesis of dihydropyrimidin-2(1H)-ones/thiones and their antidiabetic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]